Nachrichten zur Mesoblast Ltd. Aktie

Mesoblast stock soars on FDA approval of Ryoncil By Investing.com

Mesoblast stock soars on FDA approval of Ryoncil…

Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines…

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

The FDA approves Mesoblasts Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft versus host disease. Shares rise.…

US FDA approves Mesoblasts cell therapy for graft-versus-host disease By Reuters

US FDA approves Mesoblasts cell therapy for graft-versus-host disease…

Mesoblast to join Nasdaq Biotechnology Index

…

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapy…

Mesoblast Aktie: Wachstumsdruck verwandelt in Chancen

Die australische Biotechnologie-Firma Mesoblast verzeichnete im vergangenen Monat eine beachtliche Entwicklung an der Börse. Der Aktienkurs des Unternehmens, das sich…

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines…

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines…

Degenerative Disc Disease Drug Pipeline Research Report 2024 Featuring Spine BioPharma, Angitia Biopharmaceuticals, Mesoblast, BioRestorative Therapies, and DiscGenics, Inc.

Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Degenerative Disc Disease - Pipeline Insight, 2024" clinical trials has…

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to…

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines…

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

NEW YORK, March 10, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines…

Mesoblast rises after cell therapy gets FDA rare pediatric disease designation

…

Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug

Mesoblasts (MESO) Revascor (rexlemestrocel-L) gets FDAs Rare Pediatric Disease designation for treating children with congenital heart disease. Shares rise in…

Mesoblast Has Major Hurdles

…

5 Stocks to Ride the Santa Claus Rally

Mesoblast (MESO), Coinbase (COIN), Western Gas (WES), JAKKS Pacific (JAKK), and Brinker International (EAT) have the potential to outperform in…

Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug

Mesoblast (MESO) partners with Blood and Marrow Transplant Clinical Trials Network to develop a pivotal study on its lead candidate,…

Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines…

Mesoblast reports Q1 results

…

Ulcerative Colitis Market to Grow Positively by 2032, Predicts DelveInsight | Key Companies - Arena, Pfizer, Abivax, InDex, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast

With time ulcerative colitis market landscape is evolving and the treatment goals continue to shift hence the dynamics of the…

Acute Respiratory Distress Syndrome Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Leading Companies to Watch Out - MediciNova, Mesoblast, Veru, Pluristem, Avalo, Boehringer Ingelheim, Genentech, Windtree

The acute respiratory distress syndrome market size shall grow during the forecast period (2023–2032) owing to the launch of upcoming…

Why Shares of Mesoblast Are Down Monday

The companys shares continued to tumble after it received a Complete Response Letter last week from the FDA....…

ADRs End Mostly Higher, Missfresh and Mesoblast Trade Actively

ADRs End Mostly Higher, Missfresh and Mesoblast Trade Actively...…

Why Shares of Mesoblast Are Plunging Friday

The company received a Complete Response Letter from the FDA regarding its prospective graft-versus-host disease therapy....…

Mesoblast plunges as William Blair downgrades on FDA rejection

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Mesoblast ADSs Plunge Premarket on Latest FDA Rejection >MESO

Mesoblast ADSs Plunge Premarket on Latest FDA Rejection >MESO...…

Mesoblast cell therapy for graft versus host disease rejected in U.S.

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

XFRA : LWB: Wiederaufnahme/Resumption

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

Mesoblast (ASX:MSB) shares plummet on FDA setback

The US Food and Drug Administration (FDA) has rejected Mesoblast’s (MSB) resubmission…...…

UPDATE 1-Mesoblast shares tank after US FDA rejects cell therapy for children

... (Reuters) - The U.S. health regulator rejected Mesoblasts cell therapy......…

Mesoblast shares tank after US FDA delays stem cell approval again

The US regulator has again asked for more data on the stem cell treatment makers flagship product, which was blocked…

Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines…

dpa-AFX ProFeed